Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
AstraZeneca
Express Scripts
McKesson
Dow

Last Updated: January 27, 2023

Rucaparib camsylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for rucaparib camsylate and what is the scope of patent protection?

Rucaparib camsylate is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and seventy-nine patent family members in fifty-three countries.

One supplier is listed for this compound.

Summary for rucaparib camsylate
International Patents:279
US Patents:12
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 25
Clinical Trials: 6
Patent Applications: 11
DailyMed Link:rucaparib camsylate at DailyMed
Recent Clinical Trials for rucaparib camsylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alliance for Clinical Trials in OncologyPhase 3
National Cancer Institute (NCI)Phase 3
Clovis Oncology, Inc.Phase 2

See all rucaparib camsylate clinical trials

Pharmacology for rucaparib camsylate

US Patents and Regulatory Information for rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for rucaparib camsylate

Country Patent Number Title Estimated Expiration
Cyprus 1110335 See Plans and Pricing
Argentina 080164 SALES Y POLIMORFOS DE 8-FLUORO-2-{4-[(METILAMINO)METIL]FENIL}-1,3,4,5-TETRAHIDRO-6H-ACEPINO[5,4,3-CD]INDOL-6-ONA See Plans and Pricing
South Africa 200507097 Phthalazinone derivatives See Plans and Pricing
Slovenia 1660095 See Plans and Pricing
Eurasian Patent Organization 009469 ПРОИЗВОДНЫЕ ФТАЛАЗИНОНА (PHTHALAZINONE DERIVATIVES) See Plans and Pricing
Russian Federation 2006105652 ТРИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ПАРП See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for rucaparib camsylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1633724 596 Finland See Plans and Pricing
1633724 2015/016 Ireland See Plans and Pricing PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
2534153 2018039 Norway See Plans and Pricing PRODUCT NAME: RUKAPARIBKAMSYLAT; REG. NO/DATE: EU/1/17/1250 20180531
1633724 15C0022 France See Plans and Pricing PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
1633724 CR 2015 00012 Denmark See Plans and Pricing PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216
2534153 300958 Netherlands See Plans and Pricing PRODUCT NAME: RUCAPARIB CAMSYLAAT; REGISTRATION NO/DATE: EU/1/17/1250 20180529
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Johnson and Johnson
McKesson
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.